By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Medivation, Inc. 

525 Market Street
36th Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at


October 1995


Founders: Clarence Patrick and David Hung

CEO and Co-founder: David Hung

CMO (Medical): Mohammad Hirmand

CFO: Jennifer Jarrett


Please click here for medivation job opportunities.


Please click here for clinical trial information.


All Productions

Key Statistics

Ownership: Public

Web Site: Medivation
Employees: 18
Symbol: MDVN



Company News
Pfizer (PFE) Sheds More After Unloading Medivation (MDVN)'s Mission Bay Space 5/9/2017 8:15:03 AM
Why Former Medivation (MDVN) CEO and a Once-Failed Alzheimer's Drug Could be a Recipe for Disaster for Axovant (AXON) 4/19/2017 5:56:07 AM
And He's Back! Medivation (MDVN)'s David Hung to Helm Vivek Ramaswamy's Axovant (AXON) 4/10/2017 7:39:11 AM
JPM17: Surprise! Pfizer (PFE) is Still Deal Hungry for M&As After Medivation (MDVN) 1/12/2017 5:56:20 AM
Pfizer (PFE) Completes Acquisition Of Medivation (MDVN) 9/28/2016 7:52:58 AM
Pfizer (PFE) Announces Expiration Of HSR Waiting Period For Proposed Acquisition of Medivation (MDVN) 9/23/2016 8:29:03 AM
4 Biotechs Gilead (GILD) Could Be Targeting After Losing Medivation (MDVN) 9/21/2016 6:40:42 AM
Pfizer (PFE) May No Longer Need to Split Post-Medivation (MDVN) 9/16/2016 6:49:29 AM
How Medivation (MDVN) and This Little Biotech Turned $8,000 Into $250,000+ for Investors 9/13/2016 6:56:19 AM
The 3 Most-Coveted Cancer Acquisition Targets Post-Medivation (MDVN) 9/9/2016 5:58:11 AM